Male breast cancer: a report of 25 cases.
Adult
Aged
Aged, 80 and over
Breast Neoplasms, Male
/ diagnosis
Carcinoma, Ductal, Breast
/ diagnosis
Carcinoma, Lobular
/ diagnosis
Delayed Diagnosis
Follow-Up Studies
Humans
Lymphatic Metastasis
Male
Mastectomy
/ statistics & numerical data
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Retrospective Studies
Survival Rate
Breast cancer
clinical
male
pathological features
survival
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
10
05
2020
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
7
4
2021
Statut:
epublish
Résumé
Male breast cancer is a rare disease accounting for less than 1% of all breast cancer diagnoses worldwide to our knowledge. The aim of this retrospective study is to analyse the epidemiologic, clinical, therapeutic and evolutive profiles of this disease and to compare some cancer aspects between male and female in 25 cases collected at Mohamed VI Oncology Center at the University Hospital of Casablanca between 2012 and 2018. Of all breast cancers, men with breast cancer make up a minority. Male compared to female breast cancers occurred later in life with higher stage and more estrogen receptor-positive tumors. The median age was 67.7 years. The average diagnosis delay was 15.7 month. Cancer was discovered through self examination in 76.1% of cases. The mean diameter was 3.5 cm and range from 1-6 cm. According to the tumor-node-metastasis (TNM) classification, tumors were classified as T1-T2 (40%) and T3-T4 (60%). Infiltrating ductal carcinoma was the most frequent (92%) and 1 case of lobular carcinoma. Axillary nodal involvement was present in 82.4% of cases. Hormonal receptors were positive in 83% of cases. 86.6% of our cases present metastasis. Bone was the most representative site. Surgery was usually mastectomy with axillary clearance. It was possible to follow 21 of the patients. The median of follow-up was 12 months. The evolution has been characterized by local recurrence in 6 cases. There was 9 cases of death. Death was usually due to comorbid disease and to the advanced age. The 5 years overall survival rates were 57%.
Identifiants
pubmed: 33738031
doi: 10.11604/pamj.2020.37.343.23004
pii: PAMJ-37-343
pmc: PMC7934185
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343Informations de copyright
Copyright: Majdouline El Fouhi et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Cancer Res. 1998 Apr 1;58(7):1367-71
pubmed: 9537231
Maturitas. 2010 Apr;65(4):308-14
pubmed: 20138719
Jpn J Clin Oncol. 2001 Sep;31(9):444-6
pubmed: 11689599
Clin Breast Cancer. 2011 Mar;11(1):39-45
pubmed: 21421521
Cancer. 1998 Aug 1;83(3):498-509
pubmed: 9690543
Gynecol Obstet Fertil. 2014 Mar;42(3):149-54
pubmed: 22521987
Gynecol Obstet Fertil. 2008 Apr;36(4):386-94
pubmed: 18424216
Arch Intern Med. 1983 Feb;143(2):237-40
pubmed: 6824391
J Natl Cancer Inst. 1995 Feb 1;87(3):175-82
pubmed: 7707404
Tumori. 2007 Mar-Apr;93(2):225-7
pubmed: 17557578
Med Oncol. 2008;25(3):294-8
pubmed: 18074245
Australas Radiol. 1998 Feb;42(1):16-9
pubmed: 9509597
Ann Vasc Surg. 2013 Nov;27(8):1188.e9-11
pubmed: 23988541
East Mediterr Health J. 2011 Dec;17(12):930-6
pubmed: 22355946
Ann Epidemiol. 2005 Nov;15(10):773-80
pubmed: 16257362
Onkologie. 2008 Oct;31(10):505-6
pubmed: 18854647
Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55
pubmed: 19427229
Pan Afr Med J. 2016 Oct 06;25:74
pubmed: 28292037
N Y State J Med. 1988 Jun;88(6):293-6
pubmed: 2841627
Arch Surg. 2004 Oct;139(10):1079-82
pubmed: 15492147
Cancer Radiother. 2010 Dec;14(8):698-703
pubmed: 20674443
J Clin Oncol. 2010 Jan 10;28(2):232-9
pubmed: 19996029
Pan Afr Med J. 2012;13:91
pubmed: 23396646
Br J Cancer. 2001 Feb;84(4):482-8
pubmed: 11207042
Rozhl Chir. 2010 Oct;89(10):612-8
pubmed: 21374944
Int J Dermatol. 2000 Dec;39(12):881-6
pubmed: 11168652